RETRACTED: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2
Authors:
- 15 October 2004
- journal article
- retracted article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (20) , 7439-7446
Abstract
Accumulating evidence suggests an important role for cyclooxygenase-2 (COX-2) in the pathogenesis of a wide range of malignancies. Here we tested the hypothesis that the COX-2 product prostaglandin E2 (PGE2) increases cellular invasive potential by inducing matrix metalloproteinase-2 (MMP-2) expression and activity through an extracellular signal-regulated kinase (ERK)/Ets-1-dependent mechanism in pancreatic cancer. PANC-1 and MIAPaCa-2 pancreatic cancer cells were treated with PGE2 or rofecoxib, a selective COX-2 inhibitor. MMP-2 expression and activity were assayed using Western blot analysis and zymography, respectively. MMP-2 promoter activity was analyzed with a luciferase-based assay. Ets-1 activity was analyzed using gel shift assay. Ets-1 expression was specifically silenced using RNA interference. Cellular invasive and migratory potentials were determined using a Boyden chamber assay with or without Matrigel, respectively. Exogenous PGE2 induced MMP-2 expression and activity and increased ERK1/2 phosphorylation, Ets-1 binding activity, and MMP-2 promoter activity. PGE2 also increased cellular migratory and invasive potentials. The mitogen-activated protein kinase kinase inhibitor PD98059 and Ets-1 silencing each abolished PGE2-induced increases in MMP-2 expression. PD98059 and Ets-1 silencing each abrogated the effect of PGE2 on cellular invasive potential but not on cellular migratory potential. Rofecoxib suppressed MMP-2 expression and activity, Ets-1 binding activity, MMP-2 promoter activity, and cellular migratory and invasive potentials. These results suggest that PGE2 mediates pancreatic cancer cellular invasiveness through an ERK/Ets-1-dependent induction of MMP-2 expression and activity. They also suggest that COX-2 inhibition may represent a strategy to inhibit invasive potential in pancreatic cancer.Keywords
This publication has 40 references indexed in Scilit:
- Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cellsOncogene, 2003
- Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancerOncogene, 2002
- Nonsteroidal Anti-inflammatory Drugs Inhibit Matrix Metalloproteinase-2 via Suppression of the ERK/Sp1-mediated TranscriptionJournal of Biological Chemistry, 2002
- Coexpression of Glucose Transporter 1 and Matrix Metalloproteinase-2 in Human CancersJNCI: Journal of the National Cancer Institute, 2002
- TNFα induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2Atherosclerosis, 2001
- Aspirin Inhibits Matrix Metalloproteinase-2 Activity, Increases E-Cadherin Production, and Inhibits in Vitro Invasion of Tumor CellsBiochemical and Biophysical Research Communications, 2001
- EXPRESSION OF CYCLOOXYGENASE (COX) -1 AND COX-2 IN HUMAN INVASIVE TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDERJournal of Urology, 1999
- Induction of Ets-1 in endothelial cells during reendothelialization after denuding injuryJournal of Cellular Physiology, 1998
- Synergistic Transcriptional Activation of the Tissue Inhibitor of Metalloproteinases-1 Promoter via Functional Interaction of AP-1 and Ets-1 Transcription FactorsJournal of Biological Chemistry, 1996
- Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.Gut, 1994